Compounds > 1-azabicyclo(2.2.2)oct-3-yl 2-hydroxy-2-(1-iodo-1-propen-3-yl)-2-phenylacetate
Page last updated: 2024-12-11
1-azabicyclo(2.2.2)oct-3-yl 2-hydroxy-2-(1-iodo-1-propen-3-yl)-2-phenylacetate
Description
The compound you described, **1-azabicyclo(2.2.2)oct-3-yl 2-hydroxy-2-(1-iodo-1-propen-3-yl)-2-phenylacetate**, is a complex organic molecule with a unique structure. While it doesn't have a common name or widely recognized importance in scientific research, it's possible it might be relevant in niche areas, such as:
**1. Potential as a Drug Lead:**
* The molecule contains a bicyclic amine (1-azabicyclo(2.2.2)octane) that is commonly found in pharmaceuticals.
* The 2-hydroxy-2-(1-iodo-1-propen-3-yl)-2-phenylacetate side chain could be modified to create pharmacologically active molecules.
* The presence of iodine could make it suitable for radiolabeling, useful in imaging studies.
**2. Synthesis and Chemical Studies:**
* The molecule's complex structure could make it a valuable starting point for developing new synthetic methods.
* Its synthesis could involve interesting reactions and provide insights into organic chemistry principles.
* The presence of the iodine atom offers opportunities for studying chemical transformations and reactivity.
**3. Potential as a Probe:**
* Due to its structure, it could be used as a probe for studying biological systems.
* The iodine atom could be exploited to study its interactions with proteins or other molecules.
* It could potentially act as a fluorescent probe or a substrate for enzymatic reactions.
**Important Note:**
* Without further information, it's impossible to pinpoint the exact importance of this molecule.
* Its relevance might be specific to a particular research group or project.
* To understand the significance of this compound, additional context is required, such as the purpose of its synthesis or its potential applications.
Therefore, while 1-azabicyclo(2.2.2)oct-3-yl 2-hydroxy-2-(1-iodo-1-propen-3-yl)-2-phenylacetate itself might not be a well-known molecule, its unique structure and potential applications make it an intriguing subject for further research.
1-azabicyclo(2.2.2)oct-3-yl 2-hydroxy-2-(1-iodo-1-propen-3-yl)-2-phenylacetate: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 6438797 |
MeSH ID | M0215146 |
Synonyms (7)
Synonym |
iqnp |
1-azabicyclo[2.2.2]octan-3-yl (e)-2-hydroxy-5-iodo-2-phenylpent-4-enoate |
3-quinuclidinyl alpha-hydroxy-alpha-(1-iodo-1-propen-3-yl)-alpha-phenylacetate |
1-azabicyclo(2.2.2)oct-3-yl alpha-hydroxy-alpha-(1-iodo-1-propen-3-yl)-alpha-phenylacetate |
147612-55-3 |
benzeneacetic acid, alpha-hydroxy-alpha-(3-iodo-2-propenyl)-, 1-azabicyclo(2.2.2)oct-3-yl ester |
1-azabicyclo(2.2.2)oct-3-yl 2-hydroxy-2-(1-iodo-1-propen-3-yl)-2-phenylacetate |
Research
Studies (12)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 9 (75.00) | 18.2507 |
2000's | 3 (25.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.59
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 11.59 (24.57) | Research Supply Index | 2.56 (2.92) | Research Growth Index | 4.16 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 12 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |